

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Last Update: Mar 10, 2025

A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases

ClinicalTrials.gov Identifier:

[NCT05552469](#)

Novartis Reference Number: CDFV890G12101

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS) and lower risk chronic myelomonocytic leukemia (LR CMML). This research study is to find out if study treatment DFV890 is safe and tolerable, and can help patients who were diagnosed with a myeloid disease such as: very low, low or intermediate risk myelodysplastic syndromes (MDS) and very low, low or intermediate risk chronic myelomonocytic leukemia (CMML). The study seeks to determine the optimal dose of DFV890 that is safe and efficacious in patients with myeloid disease. The effectiveness and safety/tolerability of the study treatment is not yet confirmed in this disease setting.

Eligible patients meeting all study entry requirements will be required to provide a sample from their bone marrow at screening and at select study timepoints. All enrolled patients will be dosed for a minimum of twenty-four weeks (6 cycles of treatment) unless they experience side effects related to the study treatment requiring dose interruption/discontinuation, worsening of the disease, and/or if treatment is discontinued at the discretion of the investigator or the patient.

Condition

Myeloid Diseases

Phase

Phase1

Overall Status

Recruiting

Number of Participants

80

Start Date

May 08, 2023

Completion Date

Jun 30, 2026

Gender

All

Age(s)

18 Years - 100 Years (Adult, Older Adult)

Interventions

Drug

DFV890

DFV890 Single Agent

Eligibility Criteria

Key Inclusion Criteria:

1. Patients must be ≥ 18 years of age at the time of signing the informed consent form (ICF)
2. The Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
3. Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutions guidelines and must be willing to undergo a bone marrow aspirate.
4. Patients must have one of the following for eligibility into the study:
 1. In dose optimization and expansion: IPSS-R defined very low, low or intermediate risk Myelodysplastic Syndrome (LR MDS) who failed to respond to or did not tolerate ESAs or luspatercept or HMAs and patients with del 5q who failed to respond to or did not tolerate lenalidomide; or
 2. In dose optimization and expansion: IPSS-R defined very low, low or intermediate risk Chronic Myelomonocytic Leukemia (LR CMML) who failed to respond to or did not tolerate hydroxyurea or HMAs.

Key Exclusion Criteria:

1. Systemic antineoplastic therapy (including cytotoxic chemotherapy, alpha-interferon, kinase inhibitors or other targeted small molecules, and toxin-immunoconjugates) or any experimental therapy within 28 days or 5 half-lives, whichever is longer, and recovered from the toxicities before the first dose of study treatment. For patients that received antibodies the washout period is 4 weeks prior to study treatment.
2. History of hypersensitivity to the study treatment or its excipients or to drugs of similar chemical classes.
3. Patients who have previously been treated with agents that have the same mechanism of action as DFV890 as defined in Table 6-8, list of prohibited medications (e.g., drugs targeting the NLRP3 inflammasome pathway and the IL-1 pathway (canakinumab and anakinra)).
4. Use of hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF, M-CSF), thrombopoietin mimetics or erythroid stimulating agents anytime ≤ 1 week (or 5 half lives, whichever is longer) prior to start of study treatment.
5. Patients receiving:
 1. concomitant medications that are known to be modulators of cytochrome P450 enzymes CYP2C9 and/or CYP3A (specifically strong or moderate inducers of CYP2C9, strong inducers of CYP3A enzymes, strong inhibitors of CYP2C9 and/or strong or moderate dual inhibitors of CYP2C9/CYP3A); and
 2. patients, who are poor CYP2C9 metabolizers receiving concomitant medications known to be strong or

moderate inhibitors of CYP3A, whose concomitant medications cannot be discontinued or switched to a different medication within 5 half-lives or 1 week (whichever is longer) prior to start of study treatment and for duration of the study. See Section 6.8 and list of prohibited drugs in Appendix 8 for more details.

Other protocol-defined inclusion/exclusion criteria may apply.

France

Novartis Investigative Site

Recruiting

Grenoble,38043,France

Novartis Investigative Site

Recruiting

Nantes Cedex 1,44093,France

Germany

Novartis Investigative Site

Recruiting

Velbert,North Rhine-Westphalia,42551,Germany

Novartis Investigative Site

Recruiting

Dresden,01307,Germany

Novartis Investigative Site

Recruiting

Leipzig,04103,Germany

Hong Kong

Novartis Investigative Site

Recruiting

Hong Kong,Hong Kong

Italy

Novartis Investigative Site

Recruiting

Brescia,BS,25123,Italy

Novartis Investigative Site

Recruiting

Rozzano,MI,20089,Italy

Singapore

Novartis Investigative Site

Recruiting

Singapore,119074,Singapore

Novartis Investigative Site

Recruiting

Singapore,169608,Singapore

Spain

Novartis Investigative Site

Recruiting

Madrid,28034,Spain

Novartis Investigative Site

Recruiting

Madrid,28041,Spain

United States

Univ of TX MD Anderson Cancer Cntr

Recruiting

Houston,Texas,77030,United States

Phone: 713-792-2828

Guillermo Garcia-Manero

Stanford Cancer Center

Recruiting

Stanford,California,94305,United States

Mani Gupta

Phone: [650-723-4000](tel:650-723-4000)

Email: mgupta4@stanford.edu

Peter Greenberg

Sidney Kimmel CCC At JH

Recruiting

Baltimore, Maryland, 21231, United States

Amy Elizabeth DeZern

Matthew Gagaring

Phone: [+1 410 955 5222](tel:+14109555222)

Email: mgagari1@jhmi.edu

Weill Cornell Medicine NY-Presb

Recruiting

New York, New York, 10021, United States

Pinkal Desai

Andi Rustani

Phone: [212-746-0743](tel:212-746-0743)

Email: anr4007@med.cornell.edu

Dana Farber Cancer Institute

Recruiting

Boston, Massachusetts, 02115, United States

Geoffrey Currier

Phone: [617-632-5136](tel:617-632-5136)

Email: Geoffreya_currier@dfci.harvard.edu

Max Stahl

Memorial Sloan Kettering Cancer Ctr

Recruiting

New York, New York, 10065, United States

Gabrielle Melamed

Phone: [212-639-3854](tel:212-639-3854)

Email: melamedg@mskcc.org

Tamanna Haque

H Lee Moffitt Cancer Center and Research Institute

Recruiting

Tampa,Florida,33612,United States

Cyril Patra

Phone: [813-972-8391](tel:813-972-8391)

Email: cyril.patra@moffitt.org

Zhuoer Xie

Mayo Clinic Rochester

Recruiting

Rochester,Minnesota,55905,United States

Abhishek Mangaonkar

Misty Keller

Phone: [507-284-2467](tel:507-284-2467)

Email: Keller.Misty@mayo.edu

Vanderbilt University Medical Ctr

Recruiting

Nashville,Tennessee,37232,United States

Phone: [615-322-5000](tel:615-322-5000)

Ashwin Kishtagari

Northwestern University

Recruiting

Chicago,Illinois,60611,United States

Alesi Monterroso

Phone: [410-328-6896](tel:410-328-6896)

Email: alesi.monterroso@northwestern.edu

Yasmin Abaza

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email:

Novartis Pharmaceuticals

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: novartis.email@novartis.com

Source URL: <https://prod1.novartis.com/clinicaltrials/study/nct05552469>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05552469>
2. [#trial-eligibility](#)
3. <tel:713-792-2828>
4. <tel:650-723-4000>
5. <mailto:mgupta4@stanford.edu>
6. [tel:+1 410 955 5222](tel:+14109555222)
7. <mailto:mgagari1@jhmi.edu>
8. <tel:212-746-0743>
9. <mailto:anr4007@med.cornell.edu>
10. <tel:617-632-5136>
11. mailto:Geoffreya_currier@dfci.harvard.edu
12. <tel:212-639-3854>
13. <mailto:melamedg@mskcc.org>
14. <tel:813-972-8391>
15. <mailto:cyril.patra@moffitt.org>
16. <tel:507-284-2467>
17. <mailto:Keller.Misty@mayo.edu>
18. <tel:615-322-5000>
19. <tel:410-328-6896>
20. <mailto:alesi.monterroso@northwestern.edu>
21. <tel:+41613241111>
22. <mailto:>
23. <tel:1-888-669-6682>
24. <mailto:novartis.email@novartis.com>